Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK plus NSCLC): Primary Results from Phase III Study (J-ALEX)

被引：5

作者：

Kim, Young ^{[1
]}

Hida, Toyoaki ^{[2
]}

Nokihara, Hiroshi ^{[3
]}

Kondo, Masashi ^{[4
]}

Azuma, Koichi ^{[5
]}

Seto, Takashi ^{[6
]}

Takiguchi, Yuichi ^{[7
]}

Nishio, Makoto ^{[8
]}

Yoshioka, Hiroshige ^{[9
]}

Imamura, Fumio ^{[10
]}

Hotta, Katsuyuki ^{[11
]}

Watanabe, Satoshi ^{[12
]}

Goto, Koichi ^{[13
]}

Nakagawa, Kazuhiko ^{[14
]}

Mitsudomi, Tetsuya ^{[15
]}

Yamamoto, Nobuyuki ^{[16
]}

Kuriki, Hiroshi ^{[17
]}

Asabe, Ryoichi ^{[17
]}

Tanaka, Tomohiro ^{[18
]}

Tamura, Tomohide ^{[19
]}

机构：

[1] Kyoto Univ, Kyoto, Japan

[2] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[3] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[4] Nagoya Univ, Resp Med, Nagoya, Aichi, Japan

[5] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Kurume, Fukuoka, Japan

[6] Natl Kyushu Canc Ctr, Fukuoka, Japan

[7] Chiba Univ, Grad Sch Med, Dept Med Oncol, Chiba, Japan

[8] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan

[9] Kurashiki Cent Hosp, Kurashiki, Okayama, Japan

[10] Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Japan

[11] Okayama Univ Hosp, Okayama, Japan

[12] Osaka Med Ctr Canc & Cardiovasc Dis, Niigata, Japan

[13] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Chiba, Japan

[14] Kindai Univ, Fac Med, Osaka, Japan

[15] Kindai Univ, Fac Med, Dept Surg, Div Thorac Surg, Osaka, Japan

[16] Wakayama Med Univ, Internal Med, Wakayama, Japan

[17] Chugai Pharmaceut Co Ltd, Tokyo, Japan

[18] Chugai Pharmaceut Co Ltd, Clin Sci & Strategy Dept, Tokyo, Japan

[19] St LukeS Int Hosp, Tokyo, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

ALK Inhibitor; ALK plus NSCLC;

D O I：

10.1016/j.jtho.2016.11.427

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA07.03

引用

页码：S378 / S379

页数：2

共 50 条

[31] Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naive advanced ALK plus non-small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study
Zhou, C.
Lu, Y.
Kim, S-W.
Baisamut , T.
Zhou, J.
Zhang, Y.
He, J.
Yang, J.
Cheng, Y.
Lee, S-H.
Chang, J.
Fang, J.
Liu, Z.
Bu, L.
Qian, L.
Xu, T.
Archer, V.
Hilton, M.
Zhou, M.
Zhang, L.
ANNALS OF ONCOLOGY, 2022, 33 : S1563 - S1563
[32] BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA
Rosado-Buzzo, A.
Garcia-Mollinedo, L.
Luna-Casas, G.
Mould-Quevedo, J. F.
Gutierrez-Ardila, M., V
Vargas Zea, N.
VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
[33] EFFICACY AND SAFETY OF CRIZOTINIB IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) RESULTS FROM A PHASE II GLOBAL TRIAL
Ferreira, Carlos G.
Barrios, C.
Shaw, Alice T.
Shi, Yuankai
De Pas, Tommaso M.
Yang, Pan C.
Riely, Greg J.
Crino, Lucio
Iyer, Shrividya
Polli, Anna
Lanzalone, Silvana
Kim, Dong W.
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (07) : S107 - S108
[34] Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
Popat, S.
Liu, G.
Lu, S.
Song, G.
Samnotra, V.
Yang, J. C-H.
ANNALS OF ONCOLOGY, 2019, 30
[35] Alectinib for ALK-positive non-small-cell lung cancer
Rossi, Antonio
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (08) : 1005 - 1013
[36] Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).
Choi, Briana
Alkhatib, Nimer S.
Pae, Elizabeth
Babiker, Hani M.
Garland, Linda L.
Henglefelt, Alyssa
McBride, Ali
Abraham, Ivo
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[37] Clinical effect of alectinib in patients with ALK-positive non-small cell lung cancer
Nishi, Koichi
ANNALS OF ONCOLOGY, 2019, 30
[38] Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer
Yoshida, Hironori
Kim, Young Hak
Ozasa, Hiroaki
Sakamori, Yuichi
Tsuji, Takahiro
Nomizo, Takashi
Yasuda, Yuto
Yamamoto, Tomoko
Ajimizu, Hitomi
Hirai, Toyohiro
IN VIVO, 2018, 32 (06): : 1587 - 1590
[39] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
Camidge, D. R.
Kim, H. R.
Ahn, M. -J.
Yang, J. C. -H.
Han, J. -Y.
Lee, J. -S.
Hochmair, M. J.
Li, J. Y. -C.
Chang, G. -C.
Lee, K. H.
Gridelli, C.
Delmonte, A.
Garcia Campelo, R.
Kim, D. -W.
Bearz, A.
Griesinger, F.
Morabito, A.
Felip, E.
Califano, R.
Ghosh, S.
Spira, A.
Gettinger, S. N.
Tiseo, M.
Gupta, N.
Haney, J.
Kerstein, D.
Popat, S.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21): : 2027 - 2039
[40] Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naive ALK plus advanced non-small-cell lung cancer (NSCLC)
Zhou, C.
Lu, Y.
Kim, S-W.
Reungwetwattana, T.
Zhou, J.
Zhang, Y.
He, J.
Yang, J-J.
Cheng, Y.
Lee, S. H.
Bu, L.
Xu, T.
Yang, L.
Wang, C.
Morcos, P. N.
Mitry, E.
Li, Z.
ANNALS OF ONCOLOGY, 2018, 29 : 174 - 174

← 1 2 3 4 5 →